Cellular & Gene Therapy
The Center for Biologics Evaluation and Research (CBER) regulates human gene therapy products - products that introduce genetic material into the body to replace faulty or missing genetic material, thus treating or curing a disease or abnormal medical condition. CBER uses both the Public Health Service Act and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight.
FDA has not yet approved any human gene therapy product for sale. However, the amount of gene-related research and development occurring in the United States continues to grow at a fast rate and FDA is actively involved in overseeing this activity. FDA has received many requests from medical researchers and manufacturers to study gene therapy and to develop gene therapy products. Such research could lead to gene-based treatments for cancer, cystic fibrosis, heart disease, hemophilia, wounds, infectious diseases such as AIDS, and graft-versus-host disease.
Articles and Publications
Gene Therapy Patient Tracking
- Genetic Modification Clinical Research Information Sytem (GeMCRIS) (NIH)
- Gene Therapy Patient Tracking System
- NIH News: New Human Gene Transfer Research Data System
- Recombinant DNA and Gene Transfer (NIH)
Meetings and Presentations
Product Appoval Process